onc brain

The longer read

The gap this cohort targets is structural rather than scientific. BCLC has functioned less as a description of the evidence than as an allocation algorithm, and a modality absent from the tree does not get referred, does not accrue single-institution series with survival follow-up, and therefore never assembles the OS evidence that would earn it a place. EBRT for early HCC has been stuck in that loop for two decades. Pooling individual patient data from every published series that met prespecified technical standards is the only realistic way out of it, because no one is going to randomise a BCLC-0 pt against resection at the scale required.

What the design can and cannot deliver follows directly from that. A median OS of 6.8 years in BCLC-0 and 4.6 years in BCLC-A, over 4,913 pts with 5.0 years of median follow-up, is a durable number in absolute terms and the follow-up is long enough that it is not an artifact of immature censoring. But the comparison the conclusion invites, against resection and thermal ablation, is made across literatures rather than within a trial. The pts in this cohort reached EBRT by a route that was, in most contributing centers, not first choice, which cuts in both directions: some were unresectable or medically inoperable and should have done worse, some were referred by a local preference for RT and may have been fully eligible for surgery. Neither selection pressure is measurable from published series, and IPD does not repair it, since IPD fixes the granularity of the analysis, not the provenance of the pts.

The covariate model is where the more useful signal sits. Advanced stage, tumor burden, performance status, and Child-Pugh B or C predicting mortality is confirmation the dataset behaves like HCC and not much more. Ablative dose predicting reduced mortality is the one finding that is both modifiable and RT-specific, and it moves the read from "EBRT is a reasonable option" to "ablative-dose EBRT is the thing that was associated with the outcome." That distinction matters for how the result should propagate: a center adopting EBRT for early HCC on the strength of these medians while delivering non-ablative doses is not reproducing the cohort. The abstract does not give the dose threshold or the fractionation distribution, so the operational form of that recommendation is not recoverable from the source text.

The era effect deserves more skepticism than it usually gets. Recent year of treatment predicting survival in a multi-decade pooled cohort is compatible with better planning, image guidance, and motion management, and equally compatible with stage migration from better imaging, more aggressive salvage, and the arrival of effective systemic therapy for progression after locoregional treatment. Those explanations are not separable here, and the one that flatters RT is not obviously the dominant one.

What would have to be true for this to be wrong is that the EBRT-treated pts in these series were systematically healthier or lower-burden than the resection and ablation cohorts they are being compared to. That is not the direction most clinicians would guess, which is the strongest argument for taking the result seriously. It is still not a randomised comparison, and the honest read is that this establishes EBRT as an option that belongs in the BCLC conversation, not that it establishes EBRT as equivalent to resection for a pt who could have either.